William A. Magioncalda

Will Magioncalda is an associate in the firm’s Business Law Department and a member of its Technology and Life Sciences group. He joined Goodwin in 2017.

A selection of Mr. Magioncalda’s recent representations include:

• Goldman Sachs and other underwriters in Arvinas, Inc.’s $120 million initial public offering
• Foundation Medicine, Inc. in connection with its merger with Roche at an enterprise valuation of $5.3 billion
• The underwriters in DBV Technologies’ $150 million, Albireo Pharma, Inc.’s $69.9 million, Viking Therapeutics’ $67.5 million, Eloxx Pharmaceuticals’ $57.5 million and Synlogic, Inc.’s $30 million public follow-on offerings
• Cowen as sales agent in Dynavax Technologies’ $150 million ATM offering
• Akili Interactive Labs, Inc. in its $55 million Series C financing
• Aircall in its $29 million Series B financing